EML4 and non-small cell lung carcinoma: For example, since both EGFR mutations [31] and EML4/ALK fusions [32] are more common in NSCLC non-smokers than in smokers, success of RCCTs of EGFR or EML4/ALK inhibitors in unselected patients could depend on minor variability in smoking incidence in the neighborhoods from which patients were recruited.